In another example, a bioresorbable implant for use in a nasal region includes one or more bioresorbable polymers, and a pharmaceutical composition coupled to the one or more bioresorbable polymers. A release rate of the pharmaceutical composition is related to a degradation rate of the one or more bioresorbable polymers.

The present disclosure describes an intervertebral disk replacement system. The system can include a tissue-engineered intervertebral disc that is combined with a bioresorbable stabilization system for structural guidance. The system can prevent or reduce intervertebral disk implant displacement and can increase the stiffness when compared to the implantation of the intervertebral disk implant without the stabilization system.

The present disclosure describes an intervertebral disk replacement system. The system can include a tissue-engineered intervertebral disc that is combined with a bioresorbable stabilization system for structural guidance. The system can prevent or reduce intervertebral disk implant displacement and can increase the stiffness when compared to the implantation of the intervertebral disk implant without the stabilization system.

The invention relates to bacteriophage means, namely intracorporal bacteriophage means, nasopharyngeal and pulmonary bacteriophage means, cutaneous bacteriophage means, and bacteriophage suture means, and in addition a two-syringe bacteriophage means, a nasopharyngeal and pulmonary bacteriophage means device, and a bacteriophage sensitive testing application.

Provided herein are high-throughput methods for genetic barcoding and analysis, e.g., for tagging each biomaterial apsule with a barcode cell. These barcode cells are derived from patient samples, and thus embody natural human genetic variation. Also provided are SNP panels that can be used as genetic barcodes to identify the identity of a cell.

This document relates to methods and materials for treating nerve injuries. For example, thermoresponsive compositions containing 4-aminopyridine (4-AP) and/or one or more derivatives of 4-AP as well as methods for using such thermoresponsive compositions as a delivery system for 4-AP and/or one or more derivatives of 4-AP (e.g., to treat nerve injury) are provided. This document also provides methods and materials for treating a wound (e.g., a skin wound). For example, compositions containing 4-AP and/or one or more derivatives of 4-AP can be administered (e.g., systemically administered) to a mammal having a wound (e.g., a skin wound) to treat the wound (e.g., to promote wound healing).

An implantable medical device and methods for making and using the same are provided. In various embodiments, the device comprises a central hub structure in communication with at least one housing or pod capable of containing cells and therapeutic materials. Also provided are membrane structures and methods of forming the same, the membranes comprising a gradient of varying porosity for use with devices of the present disclosure, as well as other uses.

Liquid polymer pharmaceutical compositions with a biodegradable liquid polymer, a biocompatible solvent or combination or mixture of solvents and/or co-solvents, and an active pharmaceutical agent comprising a peptide are useful to provide extended long-term release of the drug to a subject and/or to improve the stability of the active pharmaceutical agent. In embodiments, the polymer may be initiated with a low-molecular weight polyethylene glycol and/or may be a block copolymer comprising a low-molecular weight polyethylene glycol block. In further embodiments, the liquid polymer pharmaceutical composition may include a divalent cation, which may be provided in the form of a metal salt.

This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.

Active agents that bind to VEGF or a VEGF receptor and reduce the severity of a condition associated with BLB disruption and/or angiogenesis, for example anti-VEGF antibodies or tyrosine kinase inhibitor small molecules, can be locally, regionally or systemically administered to an individual with Meniere's Disease to alleviate symptoms of the disease, for example, due to edema and endolymphatic dysfunction. An effective amount of these compounds can be delivered by intratympanic or intracochlear administration. Other methods of administration include, but are not limited to, topical, parenteral, subcutaneous, intraperitoneal and intranasal. Formulations may be, for example, for immediate release, sustained release, or controlled release.